Abstract 2335P
Background
In invasive lung adenocarcinoma (LUAD), patients with micropapillary (MIP) or solid (SOL) components had a significantly poorer prognosis than those with only lepidic (LEP), acinar (ACI) or papillary (PAP) components. It is interesting to explore the genetic features of different histologic subtypes especially the highly aggressive components.
Methods
This study comprised four cohorts of patients who underwent complete surgical resection for lung adenocarcinoma (LUAD) and had their medical records reviewed. Cohort 1 depicted the distribution of different histological subtypes across tumor size groups. Logistic regression analysis in cohort 2 investigated the associations between driver mutations and histological subtypes. Cohort 3 utilized spatial whole-exome sequencing with laser-capture microdissection to identify genetic heterogeneity among histological components within the same tumor. Cohort 4, in conjunction with the cBioportal cohort, was employed to validate the findings obtained from cohort 3.
Results
Based on a cohort of 5,933 patients (cohort 1), this study observed varying prevalence of micropapillary (MIP) and solid (SOL) components in different tumor size groups. Furthermore, cohort 2 revealed that patients with ALK fusion or TP53 mutations had a higher probability of developing MIP/SOL components in cohort 2. To account for individual differences, tspatial whole-exome sequencing was performed using laser-capture microdissection on five patients with coexistent components, enabling the identification of genetic features within the same tumor. In tracing the evolution of components, we found that titin mutation might serve as a crucial intratumor potential driver for MIP/SOL components, which was validated by the cohort 4 of 146 LUAD patients undergoing bulk WES. Functional analysis demonstrated that TTN mutations were enriched the complement and coagulation cascades, which correlated with the pathway of cell adhesion, migration, and proliferation.
Conclusions
Collectively, the histologic subtypes of invasive LUAD were genetically different, and certain trunk genotypes might synergize with branching TTN mutation to develop highly aggressive components.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2222P - Frequent TERT gains in metastatic papillary thyroid carcinoma
Presenter: Sara Gil
Session: Poster session 16
2223P - Next-generation sequencing enables identification of RET rearrangements in papillary thyroid cancer
Presenter: Sergi Clavé
Session: Poster session 16
2224P - Identifying prognostic factors in patients with radioiodine-refractory differentiated thyroid carcinoma (RR-DTC) treated with tyrosine kinase inhibitors (TKI): Data from REGETNE registry
Presenter: Maria Victoria San Roman Gil
Session: Poster session 16
2225P - FOX1 (rs965513), NKX2-1 (rs944289) and BRAF (V600E) gene mutations and their role in development of papillary thyroid cancer
Presenter: Darko Katalinic
Session: Poster session 16
2226P - Survival benefit of radioiodine therapy (RAI) in papillary thyroid cancer variants (PTCV): A SEER analysis
Presenter: Sakhr Alshwayyat
Session: Poster session 16
2227P - The efficacy and safety of lenvatinib in neoadjuvant therapy in patients with locally advanced thyroid cancer: A single-arm phase II clinical trial
Presenter: Jianhong Yu
Session: Poster session 16
2228P - Long-term clinical outcomes of Lenvatinib in patients with differentiated thyroid cancer: Results from the real-world practice of a single institution
Presenter: Ryutaro Onaga
Session: Poster session 16
2229P - Updated safety and efficacy of selpercatinib in patients (pts) with RET-activated thyroid cancer: Data from LIBRETTO-001
Presenter: Lori Wirth
Session: Poster session 16
2323P - Multi-omic spatial phenotyping of the NSCLC tumour microenvironment for the development of a spatial score associated with immunotherapy resistance
Presenter: Arutha Kulasinghe
Session: Poster session 16
2324P - Trametinib and PD-1 combined blockade impairs tumor growth and improves survival of KRAS-mutant lung cancer through Id1 downregulation
Presenter: Ander Puyalto
Session: Poster session 16